Volume 73, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Preview this article:
Zoom in


| /docserver/preview/fulltext/14761645/73/5/0730821-1.gif

There is no abstract available for this article.
Use the preview function to the left.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 : 209–218. [Google Scholar]
  2. Danis M, Bricaire F, 2003. The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria. Fundam Clin Pharmacol 17 : 155–160. [Google Scholar]
  3. White NJ, Nosten F, Looareesuwan S, Watkins WM, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK 2nd, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 : 1965–1967. [Google Scholar]
  4. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo JB, Rosenthal PJ, 2005. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkino Faso. Am J Trop Med Hyg 73 : 826–832. [Google Scholar]
  5. Chulay JD, Watkins WM, Sixsmith DG, 1984. Synergistic anti-malarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg 33 : 325–330. [Google Scholar]
  6. Srivastava IK, Vaidya AB, 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43 : 1334–1339. [Google Scholar]
  7. White NJ, 2004. Antimalarial drug resistance. J Clin Invest 113 : 1084–1092. [Google Scholar]
  8. Attaran A, Barnes KI, Curtis C, D’Alessandro U, Fanello CI, Galinski ME, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF, Watkins WM, 2004. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363 : 237–240. [Google Scholar]
  9. Rojanawatsirivej C, Vijaykadga S, Amklad I, Wilairatna P, Looareesuwan S, 2003. Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 34 : 536–541. [Google Scholar]
  10. Clark RL, White TE, 2004. S AC, Gaunt I, Winstanley P and Ward SA. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71 : 380–394. [Google Scholar]
  11. Anonymous, End decade databases—Fertility and Contraceptive Use. Vol. 2005: UNICEF Statistics
  12. Steck EA, The Chemotherapy of Protozoan Diseases. Walter Reed Army Institute of Medicine, 1971
  13. Thomas F, Erhart A, D’Alessandro U, 2004. Can amodiaquine be used safely during pregnancy? Lancet Infect Dis 4 : 235–239. [Google Scholar]
  14. Olliaro P, Mussano P, Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003:CD000016 [Google Scholar]
  15. Taylor WR, White NJ, 2004. Antimalarial drug toxicity: a review. Drug Saf 27 : 25–61. [Google Scholar]
  16. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC, 1987. Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol 33 : 409–414. [Google Scholar]
  17. Ringwald P, Bickii J, Basco LK, 1998. Amodiaquine as the first-line treatment of malaria in Yaounde, Cameroon: presumptive evidence from activity in vitro and cross-resistance patterns. Trans R Soc Trop Med Hyg 92 : 212–213. [Google Scholar]
  18. Ringwald P, Bickii J, Basco LK, 1999. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 61 : 187–192. [Google Scholar]
  19. Caramello P, Canta F, Cavecchia I, Sergi G, Balbiano R, Ariaudo S, Audagnotto S, DiPerri G, 2005. Chemosusceptibility analysis of Plasmodium falciparum imported malaria in Italy. Diagn Microbiol Infect Dis 52 : 107–112. [Google Scholar]
  20. Graupner J, Gobels K, Grobusch MP, Lund A, Richter J, Haussinger D, 2005. Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. Parasitol Res 96 : 162–165. [Google Scholar]
  21. Molta NB, Oguche S, Pam SD, Omalu IC, Afolabi BM, Odujoko JB, Amajoh CN, Adeniji B, Wuyep VP, Ekanem OJ, 2003. Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria. Ann Trop Med Parasitol 97 : 663–669. [Google Scholar]
  22. Sendagire H, Kaddumukasa M, Ndagire D, Agutta C, Nassejje M, Pettersson M, Swedberg G, Kironde F, 2005. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Trop 95 : 172–182. [Google Scholar]
  23. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van Overmeir C, Ringwald P, D’Alessandro U, 2004. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 9 : 1091–1098. [Google Scholar]
  24. Basco LK, Same-Ekobo A, Ngane VF, Ndounga M, Metoh T, Ringwald P, Soula G, 2002. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ 80 : 538–545. [Google Scholar]
  25. Dinis DV, Schapira A, 1990. Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique. Bull Soc Pathol Exot 83 : 521–527; discussion 528 [Google Scholar]
  26. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ, 2002. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360 : 2031–2038. [Google Scholar]
  27. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, Kamy MR, 2003. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 68 : 127–132. [Google Scholar]
  28. Huang OL, Ouyang WC, Zhou JX, Wu Z, Zhang KY, Huang JK, Cai XZ, Pang XJ, Fu SG, Wang XF, et al., 1988. Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. Bull World Health Organ 66 : 353–358. [Google Scholar]
  29. Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A, 2005. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with non-complicated malaria. Am J Trop Med Hyg 72 : 581–585. [Google Scholar]
  30. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun Bousema J, Wassilew N, Schreiber J, Anemana SD, Cramer JP, Otchwemah RN, Sauerweim RW, Eggelte TA, Bienzle U, 2005. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10 : 512–520. [Google Scholar]
  31. Mutabingwa TK, Anthony D, Heller A, HallettR, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ, 2005. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 : 1474–1480. [Google Scholar]
  32. Schapira A, Schwalbach JF, 1988. Evaluation of four therapeutic regimens for falciparum malaria in Mozambique, 1986. Bull World Health Organ 66 : 219–226. [Google Scholar]
  33. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, Msokame C, Aponte JJ, Tanner M, Mshinda H, Menendez C, Alonso PL, 2002. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67 : 17–23. [Google Scholar]
  34. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ, 2001. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358 : 368–374. [Google Scholar]
  35. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B, 2003. Evidence b(i)ased medicine–selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326 : 1171–1173. [Google Scholar]
  36. Tierney JF, Stewart LA, 2005. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol 34 : 79–87. [Google Scholar]
  37. Schulz KF, Grimes DA, 2002. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 359 : 781–785. [Google Scholar]

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error